Becton, Dickinson and Co ((BDX)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Becton, Dickinson and Company (BDX) is conducting an investigational study titled ‘An Investigational Study to Evaluate the Safety and Performance of the BD PosiFlush™ SafeScrub on Needleless Access Devices.’ The study aims to assess the safety and performance of the BD PosiFlush™ SafeScrub, with the data intended for regulatory submission in the EU, highlighting its significance in enhancing medical device safety.
Intervention/Treatment: The study tests the BD PosiFlush™ SafeScrub device, designed to improve the safety and efficiency of needleless access devices (NADs) by ensuring effective scrubbing before flushing. The control group uses a standard pre-filled saline syringe and alcohol pad.
Study Design: This is a randomized, parallel interventional study without masking. Each participating site will have one unit conducting the treatment arm and another the control arm, focusing on basic science to gather essential data.
Study Timeline: The study began on October 22, 2024, with the last update submitted on August 18, 2025. These dates are crucial as they indicate the study’s progression and ongoing recruitment status.
Market Implications: The study’s progress may positively influence BDX’s stock performance by demonstrating innovation and commitment to safety in medical devices. This could enhance investor confidence, especially in a competitive industry where advancements in medical technology are pivotal.
The study is currently ongoing, with further details available on the ClinicalTrials portal.